[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Koegelenberg, C.F.N., Shaw, J.A., Irusen, E.M. and Lee, Y.C.G. (2018) Contemporary Best Practice in the Management of Malignant Pleural Effusion. Therapeutic Advances in Respiratory Disease, 12.
https://doi.org/10.1177/1753466618785098
|
[3]
|
Gayen, S. (2022) Malignant Pleural Effusion: Presentation, Di-agnosis, and Management. The American Journal of Medicine, 135, 1188-1192. https://doi.org/10.1016/j.amjmed.2022.04.017
|
[4]
|
Bibby, A.C., Dorn, P., Psallidas, I., et al. (2018) ERS/EACTS Statement on the Management of Malignant Pleural Effusions. European Respiratory Journal, 52, Article 1800349. https://doi.org/10.1183/13993003.00349-2018
|
[5]
|
Xu, Y.F., Chen, Y.R., Bu, F.L., et al. (2022) Chinese Herbal Injections versus Intrapleural Cisplatin for Lung Cancer Patients with Malignant Pleural Effusion: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 12, Article 942941. https://doi.org/10.3389/fonc.2022.942941
|
[6]
|
Asciak, R. and Rahman, N.M. (2018) Malignant Pleural Effusion: From Diagnostics to Therapeutics. Clinics in Chest Medicine, 39, 181-193. https://doi.org/10.1016/j.ccm.2017.11.004
|
[7]
|
Pan, P., Wu, F., Xu, Z., et al. (2021) Intrapleural Treatment in Pa-tients with Non-Small Cell Lung Cancer with malIgnant Pleural Effusions in the Real World. Thoracic Cancer, 12, 3416-3425. https://doi.org/10.1111/1759-7714.14224
|
[8]
|
Zhao, Y., Yu, L., Wang, L., et al. (2023) Current Status of and Progress in the Treatment of Malignant Pleural Effusion of Lung Cancer. Frontiers in Oncology, 12, Article 961440. https://doi.org/10.3389/fonc.2022.961440
|
[9]
|
Mallow, C., Hayes, M., Semaan, R., et al. (2018) Mini-mally Invasive Palliative Interventions in Advanced Lung Cancer. Expert Review of Respiratory Medicine, 12, 605-614. https://doi.org/10.1080/17476348.2018.1486709
|
[10]
|
Abe, S., Kaneko, M.K., Tsuchihashi, Y., et al. (2016) Anti-tumor Effect of Novel Anti-Podoplanin Antibody NZ-12 against Malignant Pleural Mesothelioma in an Orthotopic Xen-ograft Model. Cancer Science, 107, 1198-1205.
https://doi.org/10.1111/cas.12985
|
[11]
|
Wang, Z., Qiang, Y., Shen, Q., Zhu, X.X. and Song, Y. (2022) Neoadju-vant Programmed Cell Death Protein 1 Blockade Combined with Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series. Frontiers in Oncology, 12, Article 779251. https://doi.org/10.3389/fonc.2022.779251
|
[12]
|
Acencio, M.M.P., Puka, J., Alvarenga, V.A., et al. (2017) Intra-pleural Targeted Therapies (Anti-VEGF and Anti-EGFR) in the Model of Malignant Pleural Effusion. Oncotarget, 8, 105093-105102.
https://doi.org/10.18632/oncotarget.21362
|
[13]
|
Sabang, R.L., Gandhiraj, D., Fanucchi, M. and Epelbaum, O. (2018) Role of Bevacizumab in the Management of the Patient with Malignant Pleural Effusion: More Questions than Answers. Expert Review of Respiratory Medicine, 12, 87-94.
https://doi.org/10.1080/17476348.2018.1417042
|
[14]
|
Pilling, J.E., Dusmet, M.E., Ladas, G. and Goldstraw, P. (2010) Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion. Journal of Thoracic On-cology, 5, 1544-1550.
https://doi.org/10.1097/JTO.0b013e3181e95cb8
|
[15]
|
Fortin, M. and Tremblay, A. (2015) Pleural Controversies: Indwelling Pleural Catheter vs. Pleurodesis for Malignant Pleural Effusions. Journal of Thoracic Disease, 7, 1052-1057.
|
[16]
|
Brogi, E., Gargani, L., Bignami, E., et al. (2017) Thoracic Ultrasound for Pleural Effusion in the In-tensive Care Unit: A Narrative Review from Diagnosis to Treatment. Critical Care, 21, Article No. 325.
https://doi.org/10.1186/s13054-017-1897-5
|
[17]
|
Petrov, R., Bakhos, C. and Abbas, A.E. (2018) Management of Malignant Lung Entrapment, the Oncothorax. Thoracic Surgery Clinics, 28, 81-90. https://doi.org/10.1016/j.thorsurg.2017.08.009
|
[18]
|
Olden, A.M. and Holloway, R. (2010) Treatment of Malignant Pleural Effusion: PleuRx® Catheter or Talc Pleurodesis? A Cost-Effectiveness Analysis. Journal of Palliative Medicine, 13, 59-65. https://doi.org/10.1089/jpm.2009.0220
|
[19]
|
Cavazzoni, E., Bugiantella, W., Graziosi, L., Franceschini, M.S. and Donini, A. (2013) Malignant Ascites: Pathophysiology and Treatment. International Journal of Clinical On-cology, 18, 1-9. https://doi.org/10.1007/s10147-012-0396-6
|
[20]
|
Chen, C.D., Wang, C.L., Yu, C.J., et al. (2014) Targeted Proteomics Pipeline Reveals Potential Biomarkers for the Diagnosis of Metastatic Lung Cancer in Pleural Effu-sion. Journal of Proteome Research, 13, 2818-2829.
https://doi.org/10.1021/pr4012377
|
[21]
|
Yoon, D.W., Cho, J.H., Choi, Y.S., et al. (2016) Predictors of Survival in Patients Who Underwent Video-Assisted Thoracic Surgery Talc Pleurodesis for Malignant Pleural Effusion. Thoracic Cancer, 7, 393-398.
https://doi.org/10.1111/1759-7714.12354
|
[22]
|
Xia, H., Wang, X.J., Zhou, Q., Shi, H.Z. and Tong, Z.H. (2014) Ef-ficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis. PLOS ONE, 9, e87060. https://doi.org/10.1371/journal.pone.0087060
|
[23]
|
Dipper, A., Jones, H.E., Bhatnagar, R., Preston, N.J., Maskell, N. and Clive, A.O. (2020) Interventions for the Management of Malignant Pleural Effusions: A Network Meta-Analysis. Cochrane Database of Systematic Reviews, No. 4, CD010529. https://doi.org/10.1002/14651858.CD010529.pub3
|
[24]
|
Shimoda, M., Tanaka, Y., Hiramatsu, M., et al. (2022) Analysis of Factors Predicting the Application of Chemical Pleurodesis for Pneumothorax: An Observational Study. Medicine (Baltimore), 101, e28537.
https://doi.org/10.1097/MD.0000000000028537
|
[25]
|
Su, W.C., Lai, W.W., Chen, H.H., et al. (2003) Combined Intrapleural and Intravenous Chemotherapy, and Pulmonary Irradiation, for Treatment of Patients with Lung Cancer Pre-senting with Malignant Pleural Effusion. A Pilot Study. Oncology, 64, 18-24. https://doi.org/10.1159/000066516
|
[26]
|
Zhao, W.Y., Chen, D.Y., Chen, J.H. and Ji, Z.N. (2014) Effects of In-tracavitary Administration of Endostar Combined with Cisplatin in Malignant Pleural Effusion and Ascites. Cell Bio-chemistry and Biophysics, 70, 623-628.
https://doi.org/10.1007/s12013-014-9965-9
|
[27]
|
Li, J., Ye, T., Liu, Y., et al. (2019) Transcriptional Activation of Gstp1 by MEK/ERK Signaling Confers Chemo-Resistance to Cisplatin in Lung Cancer Stem Cells. Frontiers in Oncolo-gy, 9, Article 476.
https://doi.org/10.3389/fonc.2019.00476
|
[28]
|
Horio, F., Ikeda, T., Arake, Y., et al. (2022) Consistency between Patients and Families in Recognizing Cancer Chemotherapy Side Effects: A Questionnaire Survey. Cancer Reports (Ho-boken), 5, e1451.
https://doi.org/10.1002/cnr2.1451
|
[29]
|
Li, Q., Hu, C., Su, S., et al. (2022) Non-Small Cell Lung Cancer with Ma-lignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment. Cancer Management and Research, 14, 3347-3358.
https://doi.org/10.2147/CMAR.S385818
|
[30]
|
Watanabe, S.I., Nakagawa, K., Suzuki, K., et al. (2017) Neoadjuvant and Adjuvant Therapy for Stage III Non-Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 47, 1112-1118. https://doi.org/10.1093/jjco/hyx147
|
[31]
|
Reboul, F.L. (2004) Radiotherapy and Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: Preclinical and Early Clinical Data. Hematology/Oncology Clinics of North America, 18, 41-53.
https://doi.org/10.1016/S0889-8588(03)00138-2
|
[32]
|
Deng, H.Y., Li, D., Ren, Y., Wang, K. and Tang, X. (2021) Targeted Therapy Followed by Salvage Surgery and Adjuvant Therapy: A Promising Therapy for Lung Cancer with Ma-lignant Pleural Effusion from a Case Report. Frontiers in Surgery, 8, Article 659983. https://doi.org/10.3389/fsurg.2021.659983
|
[33]
|
Lee, P.H., Yang, T.Y., Chen, K.C., et al. (2021) Higher CD4/CD8 Ratio of Pleural Effusion Predicts Better Survival for Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Scientific Reports, 11, Article No. 9381.
https://doi.org/10.1038/s41598-021-89043-4
|
[34]
|
Padinharayil, H., Alappat, R.R., Joy, L.M., et al. (2022) Ad-vances in the Lung Cancer Immunotherapy Approaches. Vaccines (Basel), 10, Article 1963. https://doi.org/10.3390/vaccines10111963
|
[35]
|
Bruschini, S., Pallocca, M., Sperandio, E., et al. (2022) Deconvolu-tion of Malignant Pleural Effusions Immune Landscape Unravels a Novel Macrophage Signature Associated with Worse Clinical Outcome in Lung Adenocarcinoma Patients. The Journal for ImmunoTherapy of Cancer, 10, e004239. https://doi.org/10.1136/jitc-2021-004239
|
[36]
|
Zhou, K., Li, S., Zhao, Y. and Cheng, K. (2023) Mechanisms of Drug Resistance to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Immunology, 14, Article 1127071.
https://doi.org/10.3389/fimmu.2023.1127071
|
[37]
|
Suresh, K., Naidoo, J., Lin, C.T. and Danoff, S. (2018) Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest, 154, 1416-1423. https://doi.org/10.1016/j.chest.2018.08.1048
|
[38]
|
Li, Q., Hu, C., Su, S., et al. (2023) Failure Pattern and Radio-therapy Exploration in Malignant Pleural Effusion Non-Small Cell Lung Cancer Treated with Targeted Therapy. Fron-tiers in Oncology, 13, 974735.
https://doi.org/10.3389/fonc.2023.974735
|
[39]
|
Forde, P.M. and Ettinger, D.S. (2013) Targeted Therapy for Non-Small-Cell Lung Cancer: Past, Present and Future. Expert Review of Anticancer Therapy, 13, 745-758. https://doi.org/10.1586/era.13.47
|
[40]
|
Saito, M., Suzuki, H., Kono, K., Takenoshita, S. and Kohno, T. (2018) Treatment of Lung Adenocarcinoma by Molecular-Targeted Therapy and Immunotherapy. Surgery Today, 48, 1-8. https://doi.org/10.1007/s00595-017-1497-7
|
[41]
|
Choi, J.H., Choi, J., Chung, S.M., et al. (2019) The Clinical Effi-cacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma. Tuberculosis and Respiratory Diseases (Seoul), 82, 211-216. https://doi.org/10.4046/trd.2018.0019
|
[42]
|
Lim, Z.F. and Ma, P.C. (2019) Emerging Insights of Tumor Heteroge-neity and Drug Resistance Mechanisms in Lung Cancer Targeted Therapy. Journal of Hematology & Oncology, 12, Arti-cle No. 134.
https://doi.org/10.1186/s13045-019-0818-2
|
[43]
|
Zhou, H., Wu, W., Tang, X., Zhou, J. and Shen, Y. (2017) Effect of Hyperthermic Intrathoracic Chemotherapy (HITHOC) on the Malignant Pleural Effusion: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 96, e5532.
https://doi.org/10.1097/MD.0000000000005532
|
[44]
|
Ried, M., Potzger, T., Braune, N., et al. (2013) Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy Perfusion for Malignant Pleural Tumours: Perioperative Man-agement and Clinical Experience. European Journal of Cardio-Thoracic Surgery, 43, 801-807. https://doi.org/10.1093/ejcts/ezs418
|
[45]
|
Wang, X., Kong, M., Jin, J., Lin, Y., Jia, L. and Ye, M. (2022) The Effi-cacy and Safety of Intrapleural Hyperthermic Perfusion in Patients with Malignant Pleural Effusion Undergoing Vid-eo-Assisted Thoracic Surgery: A Single-Arm Clinical Trial. Journal of Thoracic Disease, 14, 1497-1503. https://doi.org/10.21037/jtd-22-353
|
[46]
|
Mai, Z., Feng, B., He, Q. and Feng, Q. (2021) Medical Thoracoscopic Thermal Ablation Therapy for Metastatic Pleural Tumors with Malignant Effusion: An Exploratory Retrospective Study. International Journal of General Medicine, 14, 9349-9360. https://doi.org/10.2147/IJGM.S339596
|
[47]
|
Vogl, T.J., Nour-Eldin, N.A., Albrecht, M.H., et al. (2017) Thermal Ablation of Lung Tumors: Focus on Microwave Ablation. Thermoablation von Lungentumoren: Mikrowellenablation im Fokus. Rofo, 189, 828-843.
https://doi.org/10.1055/s-0043-109010
|
[48]
|
Walker, S.P., Bintcliffe, O., Keenan, E., et al. (2022) Randomised Trial of Indwelling Pleural Catheters for Refractory Transudative Pleural Effusions. European Respiratory Journal, 59, Article 2101362.
https://doi.org/10.1183/13993003.01362-2021
|
[49]
|
Müller, H. and Guadagni, S. (2008) Regional Chemotherapy for Carcinoma of the Lung. Surgical Oncology Clinics of North America, 17, 895-xi.
|
[50]
|
Zeng, H., Tian, P. and Li, W. (2021) Progress of Liquid Biopsy in the Diagnosis and Treatment of Lung Cancer with Malignant Pleural Effusion. Chi-nese Journal of Lung Cancer, 24, 653-659.
|
[51]
|
Visser, E., Genet, S.A.A.M., de Kock, R.P.P.A., et al. (2023) Liquid Biopsy-Based Decision Support Algorithms for Diagnosis and Subtyping of Lung Cancer. Lung Cancer, 178, 28-36. https://doi.org/10.1016/j.lungcan.2023.01.014
|
[52]
|
Pisapia, P., Malapelle, U. and Troncone, G. (2019) Liquid Bi-opsy and Lung Cancer. Acta Cytologica, 63, 489-496.
https://doi.org/10.1159/000492710
|